Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from St
- PDF / 1,131,160 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 177 Views
BRIEF REPORT
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE Zhan-Guo Li . Jian-Kang Hu . Xiang-Pei Li . Yue Yang . Xing-Fu Li . Jian-Hua Xu . Xiao Zhang . Jian Xu . Chun-De Bao . Dong-Yi He . Zhi-Jun Li . Guo-Chun Wang . Xiao-Xia Zuo . Yi Liu . Zheng-Yu Xiao . Jin-Wei Chen . Xia-Fei Xin . Jing-Yang Li . Lin-Di Jiang . Meng-Ru Liu . Fei Ji . Chen-Ge Li
Received: October 19, 2020 / Accepted: November 11, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: Baricitinib is an oral, selective inhibitor of Janus kinase which demonstrates clinical efficacy in patients with rheumatoid arthritis (RA). This report aims to analyze the
Zhan-Guo Li, Jian-Kang Hu, and Xiang-Pei Li contributed equally to this work.
Electronic Supplementary Material The online version of this article (https://doi.org/10.1007/s12325020-01572-y) contains supplementary material, which is available to authorized users. Z.-G. Li (&) Y. Yang Peking University People’s Hospital, Beijing, China e-mail: [email protected]; [email protected] J.-K. Hu Jiangxi Pingxiang People’s Hospital, Pingxiang, China X.-P. Li The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China X.-F. Li Qilu Hospital of Shandong University, Jinan, China J.-H. Xu The First Affiliated Hospital of Anhui Medical University, Hefei, China
onset time of baricitinib in Chinese patients with moderately to severely active RA who had an inadequate response to methotrexate. Methods: This post hoc analysis evaluated clinical improvements of Chinese patients treated with baricitinib 4 mg once daily compared with placebo, based on data from a phase 3 study RA-BALANCE. Efficacy measures including American College of Rheumatology 20% (ACR20) response, ACR core set values, Disease Activity Score modified to include the 28 diarthrodial joint count (DAS28) using highsensitivity C-reactive protein (hsCRP), DAS28erythrocyte sedimentation rate, Simplified X. Zhang Guangdong General Hospital, Guangzhou, China J. Xu First Affiliated Hospital of Kunming Medical University, Kunming, China C.-D. Bao Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China D.-Y. He GuangHua Hospital, Shanghai, China Z.-J. Li First Affiliated Hospital of Bengbu Medical College, Bengbu, China G.-C. Wang China-Japan Friendship Hospital, Beijing, China
Adv Ther
Disease Activity Index, Clinical Disease Activity Index, DAS28-hsCRP B 3.2 response (low disease activity), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were evaluated at weeks 1, 2, 4, 8, 12, 14, 16, 20, and 24 (except for FACIT-F evaluated every 4 weeks). A logistic regression model and an analysis of covariance model were used to analyze treatment comparisons of categorical and continuous measures, respectively. Results: Statistically significant (p B 0.05) improvements were observed a
Data Loading...
